Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 8, 2015
- Accepted in final form August 25, 2015
- First Published November 12, 2015.
Author Disclosures
- Yazhong Tao, PhD*,
- Xin Zhang, MD*,
- Robert Zivadinov, MD, PhD,
- Michael G. Dwyer, PhD,
- Cheryl Kennedy, LMSW, MPH,
- Niels Bergsland, MS,
- Deepa Ramasamy, MD,
- Jacqueline Durfee, BSc,
- David Hojnacki, MD,
- Brooke Hayward, SM, MBA,
- Fernando Dangond, MD, MBA,
- Bianca Weinstock-Guttman, MD and
- Silva Markovic-Plese, MD, PhD
- Yazhong Tao, PhD*,
NONE
NONE
EMD Serona scientific advisory meeting
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xin Zhang, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
received consulting fees from EMD Serono, Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert Zivadinov, MD, PhD,
NONE
NONE
R Zivadinov received personal compensation from Biogen Idec, Claret, EMD Serono, Inc., Novartis, Sanofi-Genzyme, and Teva Pharmaceuticals for speaking
Section Editor for BMC Neurol for demyelinating diseases from 2010.
NONE
NONE
NONE
R Zivadinov received personal compensation from Biogen Idec, Claret, EMD Serono, Inc., Novartis, Sanofi-Genzyme, and Teva Pharmaceuticals for consulting fees
R Zivadinov received personal compensation from Biogen Idec, Claret, EMD Serono, Inc., Novartis, Sanofi-Genzyme, and Teva Pharmaceuticals for speaking
NONE
NONE
Dr. Zivadinov: financial support for research activities from Biogen Idec, Claret, EMD Serono, Inc., Novartis, Sanofi-Genzyme, and Teva Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael G. Dwyer, PhD,
(1) EMD Serono
NONE
NONE
NONE
NONE
NONE
NONE
(1) Claret Medical, Inc.
NONE
NONE
NONE
(1) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cheryl Kennedy, LMSW, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Niels Bergsland, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Deepa Ramasamy, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline Durfee, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Hojnacki, MD,
NONE
NONE
Biogen, Teva, EMD Serono, Genzyme
NONE
NONE
NONE
NONE
(1) Biogen idec, (2) EMD Serono, (3) Teva, (4) Genzyme
(1) Biogen idec, (2) EMD Serono, (3) Teva, (4) Pfizer, (5) Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brooke Hayward, SM, MBA,
NONE
NONE
NONE
NONE
NONE
NONE
EMD Serono, Inc., Biostatistician, 7 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fernando Dangond, MD, MBA,
NONE
NONE
NONE
NONE
NONE
NONE
Employed by EMD Serono, Inc.(pharma company). Position: Head of Global Clinical Development, Neurology. Have worked 8 years for the company.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bianca Weinstock-Guttman, MD and
National Multiple Sclerosis Society, Medical Advisory Board, 2006-Present
NONE
Advisory board and speaker engagements for Biogen & Idec; TEVA Neuroscience, EMD Serono, Pfeiser, Novartis and Acorda,, Genzyme&Sanofi, Questcor
Editorial board for Multiple Sclerosis International BMJ Neurology Journal of Multiple Sclerosis
NONE
NONE
NONE
Advisory board for Biogen & Idec; TEVA Neuroscience, EMD Serono, Novartis, Acorda, Mylan, Questcor, Genzyme&Sanofi
Advisory board and speaker engagements for Biogen & Idec; TEVA Neuroscience, EMD Serono, Genzyme, Genentech, and Novartis
NONE
NONE
research grants from Biogen Idec, EMD Serono, TEVA, Novartis, Acorda, Genzyme&Sanofi, Questcor
NIH multicenter studies NMSS DOD
NONE
National MS Society, Clinical grant for Pediatric MS Center of Excellence DOD
NONE
NONE
NONE
NONE
NONE
NONE
- Silva Markovic-Plese, MD, PhD
Advisory board, Genzyme Inc, Seono EMD, Chugai Inc., Biogen Idec, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research grant support from Chugai Inc, Genzyme Inc and EMD Serono
NIH/NINDS, CNBT ad hoc study section member
NONE
NMSS grant support
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (Y.T., X.Z., S.M.-P.) and Microbiology and Immunology (S.M.-P.), University of North Carolina at Chapel Hill; Buffalo Neuroimaging Analysis Center (R.Z., M.G.D., C.K., N.B., D.R., J.D.), Department of Neurology (R.Z., M.G.D., C.K., N.B., D.R., D.H., J.D., B.W.-G.), State University of New York at Buffalo; and EMD Serono, Inc. (B.H., F.D.), Rockland, MA.
- Correspondence to Dr. Markovic-Plese: markovic{at}email.unc.edu or Dr. Zivadinov: rzivadinov{at}bnac.net
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MSThanos Tsaktanis, Tobias Beyer, Lucy Nirschl et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2020 -
Article
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple SclerosisAna Cirac, Thanos Tsaktanis, Tobias Beyer et al.Neurology: Neuroimmunology & Neuroinflammation, July 23, 2021 -
Article
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSVeit Rothhammer, Davis M. Borucki, Maria Isabel Garcia Sanchez et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017 -
Article
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNSVeit Rothhammer, Jessica E. Kenison, Zahorong Li et al.Neurology: Neuroimmunology & Neuroinflammation, January 06, 2021